Maxim Group analyst Naz Rahman has reiterated their bullish stance on VANI stock, giving a Buy rating on March 26.
Naz Rahman has given his Buy rating due to a combination of factors related to Vivani Medical’s promising developments and strategic positioning in the biotechnology sector. The company is advancing its NanoPortal drug delivery platform, particularly with its NPM-115 and NPM-139 implants aimed at treating obesity and diabetes, which are significant areas of unmet medical need. The positive preclinical data for NPM-139, showing substantial weight loss, suggests a strong potential for success in human trials, aligning with the efficacy seen in NPM-115 studies.
Despite a reduction in the 12-month price target from $8.00 to $4.00 due to anticipated dilution from recent capital raises, Rahman sees long-term value in Vivani’s extended duration platform. This platform addresses patient adherence issues, potentially improving clinical outcomes in the growing GLP-1 and obesity treatment market. The recent private placement has bolstered the company’s cash position, ensuring operational funding into the second quarter of 2026, which supports the Buy rating despite the need for future financing.
Rahman covers the Healthcare sector, focusing on stocks such as Quoin Pharmaceuticals, Vivani Medical, and Cingulate Inc. According to TipRanks, Rahman has an average return of -23.2% and a 21.99% success rate on recommended stocks.
In another report released on March 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.